Methotrexate Injectable Recalled Due to Sterility Concerns
The Compounding Shop is recalling Methotrexate 25mg/mL Injectable vials due to FDA inspection findings regarding quality control and lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
The Compounding Shop, Inc. is recalling 19 vials of 10 mL Methotrexate 25mg/mL Injectable. The product was compounded in St. Petersburg, Florida, and distributed to locations in Florida, California, Minnesota, and Maine. All lots are affected by this recall.
The recall was initiated following FDA inspection findings that raised concerns regarding the firm's quality control processes. Specifically, the agency identified a lack of assurance of sterility for the product.
Consumers and healthcare providers who have this product should stop using it and contact The Compounding Shop, Inc. for further instructions or a return.
The recalled product
- Product
- Methotrexate 25mg/mL Injectable, 10 mL vials, Compounded by The Compounding Shop, St. Petersburg, FL
- Manufacturer
- THE COMPOUNDING SHOP, INC.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 25 recalled by THE COMPOUNDING SHOP, INC. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 25 products in this recall →Related recalls
Same manufacturer · THE COMPOUNDING SHOP, INC.
See all →- SevereMitomycin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-06-12
- SevereFDA Recalls Glutathione Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereTestosterone Cypionate Injectable Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereCompounded Injectable MIC Plus B12 Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereFDA Recalls Hydroxyprogesterone Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereCompounded Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- SevereFDA Recalls Compounded Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereCompounded Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- SevereBetamethasone Sodium Phosphate Injectable Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- HighMethotrexate Injectable Vials Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01
- SevereMethylcobalamin Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23